Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women

Emerging targeted therapies in triple-negative breast cancer

(2012) J. Crown et al.   ANNALS OF ONCOLOGY

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

(2012) Libero Santarpia et al.   BREAST CANCER RESEARCH AND TREATMENT

Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer

(2012) Tobias J. Grob et al.   BREAST CANCER RESEARCH AND TREATMENT

Updates in the treatment of basal/triple-negative breast cancer

(2012) Mythili Shastry et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

(2012) Lisa A. Carey et al.   JOURNAL OF CLINICAL ONCOLOGY

Sequence analysis of mutations and translocations across breast cancer subtypes

(2012) Shantanu Banerji et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer

(2012) Hiroki Nakajima et al.   Breast Cancer

Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial

(2011) Mogens Bernsdorf et al.   BREAST CANCER RESEARCH AND TREATMENT

Gene Expression Profiling: Changing Face of Breast Cancer Classification and Management

(2011) ROBERT WESOLOWSKI et al.   GENE EXPRESSION

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

Intratumoral Expression Level of Epidermal Growth Factor Receptor and Cytokeratin 5/6 Is Significantly Associated With Nodal and Distant Metastases in Patients With Basal-like Triple-Negative Breast Carcinoma

(2010) Lisa M. Sutton et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Diverse somatic mutation patterns and pathway alterations in human cancers

(2010) Zhengyan Kan et al.   NATURE

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer

(2009) M. D. Green et al.   ANNALS OF ONCOLOGY

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer

(2009) B. Corkery et al.   ANNALS OF ONCOLOGY

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines

(2009) Antoinette Hollestelle et al.   BREAST CANCER RESEARCH AND TREATMENT

Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes

(2009) E. A. Rakha et al.   CLINICAL CANCER RESEARCH

Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study

(2009) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Histological and molecular types of breast cancer: is there a unifying taxonomy?

(2009) Britta Weigelt et al.   Nature Reviews Clinical Oncology

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer

(2009) C. R. Graveel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers

(2008) Tatsuya Toyama et al.   BMC CANCER

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

How basal are triple-negative breast cancers?

(2008) François Bertucci et al.   INTERNATIONAL JOURNAL OF CANCER